title: Outcome of adult acute lymphoblastic leukemia in South East of iran (zahedan).
abstract: BACKGROUND
  Acute lymphoblastic leukemia is a lymphoid malignancy, resulting from autonomous proliferation of monoclonal abnormal stem cell. The aim of this study was to evaluate the response rate and prognostic factor of adult patients suffering from acute lymphoblastic leukemia, who were treated with chemotherapy in south east of Iran and demographic methods were used for this study.
  
  
  METHODS
  This study was conducted in Ali Ebne Abitaleb Hospital in south east of Iran (Zahedan) from 2003-2010. All adult patients with acute lymphoblastic leukemia in hematology ward received Vincristin, Daunorubicin, Cyclophosphamide, Prednisolone and high dose Methotrexate for induction therapy. All patients' information was recorded and multivariate analysis and survival studies were performed by using Kaplan-Meier statistics.
  
  
  RESULTS
  Sixty six adult patients entered. Mean age of them was 33 years old (16-68), that 53 (80.3%) cases were male and 13 cases were female. Fifty one (77.3%) cases experienced complete remission and 15 (22.7%) cases had no remission state. In the following year 53% ( 33) was alive with complete remission and 47% ( 31) were dead. Median survival was 13 months. In the end of study 30 cases were in complete remission and alive and 36 (54.5%) were dead.
  
  
  CONCLUSIONS
  Our results were comparable with other studies and minimally better than those studies.
authors: Dept. of Hematology and Oncology, Genetic Research Center , Ali Ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Mohammad Ali
authors: MA
authors: Mashhadi
authors: Dept. of Hematology and Oncology, Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
authors: Mohhamad Mahdi
authors: MM
authors: Koushyar
authors: Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
authors: Mehdi
authors: M
authors: Mohammadi
keywords: Acute lymphoblastic leukemia; Outcome; Stem cell
references: Cancer Epidemiol. 2011 Oct;35(5):e42-7
references: 21840285
references: Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix
references: 11147225
references: J Clin Oncol. 2004 Oct 15;22(20):4075-86
references: 15353542
references: Blood. 1996 Jan 15;87(2):495-508
references: 8555471
references: Hematology Am Soc Hematol Educ Program. 2005;:131-6
references: 16304370
references: J Clin Oncol. 2000 Feb;18(3):547-61
references: 10653870
references: Korean J Intern Med. 2003 Mar;18(1):21-8
references: 12760264
references: Indian J Hematol Blood Transfus. 2012 Mar;28(1):19-23
references: 23449749
references: Mayo Clin Proc. 2005 Nov;80(11):1517-27
references: 16295033
references: J Natl Cancer Inst. 2008 Apr 16;100(8):531
references: 18398092
references: J Antimicrob Chemother. 2010 Apr;65(4):761-8
references: 20106864
references: Blood. 2002 Feb 1;99(3):863-71
references: 11806988
references: Hematology Am Soc Hematol Educ Program. 2006;:133-41
references: 17124052
references: Eur J Haematol. 2008 Sep;81(3):242-3
references: 18485113
references: Curr Opin Oncol. 2000 Jan;12(1):3-12
references: 10687723
references: Cancer. 2003 Oct 1;98(7):1337-54
references: 14508819
references: J Pediatr Hematol Oncol. 2008 Dec;30(12):886-90
references: 19131772
references: Singapore Med J. 2011 May;52(5):370-4
references: 21633773
references: N Engl J Med. 2006 Jan 12;354(2):166-78
references: 16407512
references: Leukemia. 1992;6 Suppl 2:148-52
references: 1578919
references: Int J Cancer. 2003 Oct 20;107(1):113-8
references: 12925965
references: Br J Haematol. 1997 Oct;99(1):84-92
references: 9359507